These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 36388243)

  • 21. Cardiovascular complications in cystic fibrosis: A review of the literature.
    Poore TS; Taylor-Cousar JL; Zemanick ET
    J Cyst Fibros; 2022 Jan; 21(1):18-25. PubMed ID: 34140249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recommendations for the classification of diseases as CFTR-related disorders.
    Bombieri C; Claustres M; De Boeck K; Derichs N; Dodge J; Girodon E; Sermet I; Schwarz M; Tzetis M; Wilschanski M; Bareil C; Bilton D; Castellani C; Cuppens H; Cutting GR; Drevínek P; Farrell P; Elborn JS; Jarvi K; Kerem B; Kerem E; Knowles M; Macek M; Munck A; Radojkovic D; Seia M; Sheppard DN; Southern KW; Stuhrmann M; Tullis E; Zielenski J; Pignatti PF; Ferec C
    J Cyst Fibros; 2011 Jun; 10 Suppl 2():S86-102. PubMed ID: 21658649
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical characteristics and genetic analysis of cystic fibrosis transmembrane conductance reseptor-related disease.
    Kilinc AA; Alishbayli G; Taner HE; Cokugras FC; Cokugras H
    Pediatr Int; 2020 May; 62(5):629-633. PubMed ID: 32003094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [CFTR gene variations and phenotypes in seven children].
    Wang DH; Niu C; Dai JH; Tian DY
    Zhonghua Er Ke Za Zhi; 2021 Aug; 59(8):689-694. PubMed ID: 34333923
    [No Abstract]   [Full Text] [Related]  

  • 26. Extensive
    Esposito MV; Aveta A; Comegna M; Cernera G; Iacotucci P; Carnovale V; Taccetti G; Terlizzi V; Castaldo G
    J Clin Med; 2020 Nov; 9(12):. PubMed ID: 33260873
    [No Abstract]   [Full Text] [Related]  

  • 27. Potential systemic effects of acquired CFTR dysfunction in COPD.
    Miravitlles M; Criner GJ; Mall MA; Rowe SM; Vogelmeier CF; Hederer B; Schoenberger M; Altman P
    Respir Med; 2024 Jan; 221():107499. PubMed ID: 38104786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reclassifying inconclusive diagnosis after newborn screening for cystic fibrosis. Moving forward.
    Hatton A; Bergougnoux A; Zybert K; Chevalier B; Mesbahi M; Altéri JP; Walicka-Serzysko K; Postek M; Taulan-Cadars M; Edelman A; Hinzpeter A; Claustres M; Girodon E; Raynal C; Sermet-Gaudelus I; Sands D
    J Cyst Fibros; 2022 May; 21(3):448-455. PubMed ID: 34949556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function.
    Zhang S; Shrestha CL; Kopp BT
    Sci Rep; 2018 Nov; 8(1):17066. PubMed ID: 30459435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genotype-phenotype correlation and functional studies in patients with cystic fibrosis bearing CFTR complex alleles.
    Terlizzi V; Castaldo G; Salvatore D; Lucarelli M; Raia V; Angioni A; Carnovale V; Cirilli N; Casciaro R; Colombo C; Di Lullo AM; Elce A; Iacotucci P; Comegna M; Scorza M; Lucidi V; Perfetti A; Cimino R; Quattrucci S; Seia M; Sofia VM; Zarrilli F; Amato F
    J Med Genet; 2017 Apr; 54(4):224-235. PubMed ID: 27738188
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cystic Fibrosis Transmembrane Conductance Regulator. Implications in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.
    Cantin AM
    Ann Am Thorac Soc; 2016 Apr; 13 Suppl 2():S150-5. PubMed ID: 27115950
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genotype and phenotype in cystic fibrosis.
    Zielenski J
    Respiration; 2000; 67(2):117-33. PubMed ID: 10773783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Applying Cystic Fibrosis Transmembrane Conductance Regulator Genetics and CFTR2 Data to Facilitate Diagnoses.
    Sosnay PR; Salinas DB; White TB; Ren CL; Farrell PM; Raraigh KS; Girodon E; Castellani C
    J Pediatr; 2017 Feb; 181S():S27-S32.e1. PubMed ID: 28129809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cystic fibrosis transmembrane conductance regulator functional evaluations in a G542X+/- IVS8Tn:T7/9 patient with acute recurrent pancreatitis.
    Caldrer S; Bergamini G; Sandri A; Vercellone S; Rodella L; Cerofolini A; Tomba F; Catalano F; Frulloni L; Buffelli M; Tridello G; de Jonge H; Assael BM; Sorio C; Melotti P
    World J Clin Cases; 2019 Nov; 7(22):3757-3764. PubMed ID: 31799301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Islet-intrinsic effects of CFTR mutation.
    Koivula FNM; McClenaghan NH; Harper AGS; Kelly C
    Diabetologia; 2016 Jul; 59(7):1350-1355. PubMed ID: 27033560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical implications of cystic fibrosis transmembrane conductance regulator mutations.
    Mickle JE; Cutting GR
    Clin Chest Med; 1998 Sep; 19(3):443-58, v. PubMed ID: 9759548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intestinal current measurement and nasal potential difference to make a diagnosis of cases with inconclusive
    Minso R; Schulz A; Dopfer C; Alfeis N; Barneveld AV; Makartian-Gyulumyan L; Hansen G; Junge S; Müller C; Ringshausen FCC; Sauer-Heilborn A; Stanke F; Stolpe C; Tamm S; Welte T; Dittrich AM; Tümmler B
    BMJ Open Respir Res; 2020 Oct; 7(1):. PubMed ID: 33020115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cystic Fibrosis Transmembrane Regulator Modulators: Implications for the Management of Depression and Anxiety in Cystic Fibrosis.
    Talwalkar JS; Koff JL; Lee HB; Britto CJ; Mulenos AM; Georgiopoulos AM
    Psychosomatics; 2017; 58(4):343-354. PubMed ID: 28576305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transient receptor potential canonical channel 6 links Ca2+ mishandling to cystic fibrosis transmembrane conductance regulator channel dysfunction in cystic fibrosis.
    Antigny F; Norez C; Dannhoffer L; Bertrand J; Raveau D; Corbi P; Jayle C; Becq F; Vandebrouck C
    Am J Respir Cell Mol Biol; 2011 Jan; 44(1):83-90. PubMed ID: 20203293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cystic fibrosis: candidate selection and impact of the cystic fibrosis transmembrane conductance regulator therapy.
    Lehr CJ; Pilewski JM
    Curr Opin Organ Transplant; 2022 Jun; 27(3):198-203. PubMed ID: 35184094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.